References
  1. Pagano L, Valentini CG, De Stefano V, et al. Primary plasma cell leukemia: a retrospective multicenter study of 73 patients. Ann Oncol 2011;22:1628-35
  2. Tiedemann RE, Gonzalez-Paz N, Kyle RA, Santana-Davila R, et al. Genetic aberrations and survival in plasma cell leukemia. Leukemia. 2008 May;22(5):1044-52. doi: 10.1038/leu.2008.4. Epub 2008 Jan 24. PMID: 18216867; PMCID: PMC3893817.
  3. Fernández de Larrea C, et. al; International Myeloma Working Group. Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria, and treatment recommendations by the International Myeloma Working Group. Leukemia. 2013 Apr;27(4):780-91. doi: 10.1038/leu.2012.336. Epub 2012 Nov 21. PMID: 23288300; PMCID: PMC4112539.
  4. Bladé J, Kyle RA. Nonsecretory myeloma, immunoglobulin D myeloma, and plasma cell leukemia. Hematol Oncol Clin North Am. 1999 Dec;13(6):1259-72. doi: 10.1016/s0889-8588(05)70125-8. PMID: 10626149.
  5. Ramsingh G, Mehan P, Luo J, Vij R, Morgensztern D. Primary plasma cell leukemia: a Surveillance, Epidemiology, and End Results database analysis between 1973 and 2004. Cancer. 2009 Dec 15;115(24):5734-9. doi: 10.1002/cncr.24700. PMID: 19877113.
  6. Sant M, Allemani C, Tereanu C,et al; HAEMACARE Working Group. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood. 2010 Nov 11;116(19):3724-34. doi: 10.1182/blood-2010-05-282632. Epub 2010 Jul 27. Erratum in: Blood. 2011 Mar 24;117(12):3477. PMID: 20664057.
  7. Pagano L, Valentini CG, De Stefano V, et al; for GIMEMA-ALWP (Gruppo Italiano Malattie EMatologiche dell’Adulto, Acute Leukemia Working Party: coordinator Sergio Amadori). Primary plasma cell leukemia: a retrospective multicenter study of 73 patients. Ann Oncol. 2011 Jul;22(7):1628-1635. doi: 10.1093/annonc/mdq646. Epub 2011 Jan 20. PMID: 21252060.
  8. Fernández de Larrea C, Kyle RA, Shah JJ et al; International Myeloma Working Group. Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group. Leukemia. 2013 Apr;27(4):780-91. doi: 10.1038/leu.2012.336. Epub 2012 Nov 21. PMID: 23288300; PMCID: PMC4112539.
  9. Fernández de Larrea C, Kyle R, Rosiñol L, et al. Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage. Blood Cancer J. 2021 Dec 2;11(12):192. doi: 10.1038/s41408-021-00587-0. PMID: 34857730; PMCID: PMC8640034.
  10. García-Sanz R, Orfão A, González M, et al. Primary plasma cell leukemia: clinical, immunophenotypic, DNA ploidy, and cytogenetic characteristics. Blood. 1999 Feb 1;93(3):1032-7. PMID: 9920853.
  11. Kraj M, Pogłód R, Kopeć-Szlezak J, Sokołowska U, Woźniak J, Kruk B. C-kit receptor (CD117) expression on plasma cells in monoclonal gammopathies. Leuk Lymphoma. 2004 Nov;45(11):2281-9. doi: 10.1080/10428190412331283279. PMID: 15512818.
  12. Kraj M, Kopeć-Szlęzak J, Pogłód R, Kruk B. Flow cytometric immunophenotypic characteristics of 36 cases of plasma cell leukemia. Leuk Res. 2011 Feb;35(2):169-76. doi: 10.1016/j.leukres.2010.04.021. PMID: 20553988.
  13. Fernández de Larrea C, Kyle RA, et al; International Myeloma Working Group. Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group. Leukemia. 2013 Apr;27(4):780-91. doi: 10.1038/leu.2012.336. Epub 2012 Nov 21. PMID: 23288300; PMCID: PMC4112539.
  14. Fernández de Larrea C, Kyle R, Rosiñol L, et al. Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage. Blood Cancer J 2021;11:192)
  15. Gavriatopoulou M, Musto P, et al. European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias. Leukemia. 2018 Sep;32(9):1883-1898. doi: 10.1038/s41375-018-0209-7. Epub 2018 Jul 23. PMID: 30038381
  16. Katodritou E, Terpos E, Kelaidi C, et al. Treatment with bortezomib-based regimens improves overall response and predicts for survival in patients with primary or secondary plasma cell leukemia: analysis of the Greek myeloma study group. Am J Hematol 2014;89:145-50.
  17. Van De Donk NWCJ, van der Holt B, Schjesvold FH, et al. Treatment of primary plasma cell leukemia with carfilzomib and lenalidomide-based therapy: results of the first interim analysis of the phase 2 EMN12/HOVON129 study. Blood 2019;134(Suppl 1):693.
Figure 1; peripheral morphology showing blast cells having enlarged nucleus with condensed chromatin, inconspicuous nucleoli, and scant bluish cytoplasm